ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY
Davies, A.J., Tansley Hancock, O., Cummin, T., Caddy, J., Stanton, L., Burton, C., Barrans, S., Coleman, A., Osborne, W., McKay, P., Griffiths, G., Johnson, P.Volume:
37
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.1_2632
Date:
June, 2019
File:
PDF, 207 KB
english, 2019